{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:09:43Z","timestamp":1779242983539,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:00:00Z","timestamp":1632096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:00:00Z","timestamp":1632096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Calcitonin gene-related peptide (CGRP) (receptor) antibodies (erenumab, fremanezumab and galcanezumab) are increasingly used in prophylactic treatment of migraine. In the approval studies, severely affected patients with migraine and chronic daily headache without any headache free days were excluded. Thus, less is known about the effectiveness of CGRP antibody treatment in this cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Clinical routine data of 32 patients with migraine and daily headache were analysed after three months of treatment with a CGRP antibody (16 erenumab, 7 galcanezumab, 9 fremanezumab), including changes of monthly headache days (MHD) monthly migraine days (MMD) and monthly acute medication intake (AMD) as well as migraine characteristics. Statistical analysis was performed with the Wilcoxon-Test. Migraine characteristics were analysed descriptively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The number of MHD was significantly reduced (mean reduction (standard error), p-value): (-4.2 (1.3), <jats:italic>p<\/jats:italic>\u2009=\u20090.009) as well as MMD (-4.3 (1.6), <jats:italic>p<\/jats:italic>\u2009=\u20090.033). Four patients (13\u2009%) reached a 50\u2009% reduction regarding MHD and 8 patients (25\u2009%) regarding MMD, migraine duration and intensity improved under therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Despite the low responder rate, CGRP antibodies can be effective at least in a few cases of severely affected patients with drug resistant migraine and chronic daily headache.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Retrospective registered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-021-01323-6","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T13:07:47Z","timestamp":1632143267000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience"],"prefix":"10.1186","volume":"22","author":[{"given":"Armin","family":"Scheffler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Wurthmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Nsaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Glas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagny","family":"Holle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,20]]},"reference":[{"issue":"1","key":"1323_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA et al (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21(1):32","journal-title":"J Headache Pain"},{"issue":"1","key":"1323_CR2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","volume":"21","author":"A Scheffler","year":"2020","unstructured":"Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M et al (2020) Erenumab in highly therapy-refractory migraine patients: First German real-world evidence. J Headache Pain 21(1):84","journal-title":"J Headache Pain"},{"issue":"1","key":"1323_CR3","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12883-018-1193-2","volume":"18","author":"A Camporeale","year":"2018","unstructured":"Camporeale A, Kudrow D, Sides R, Wang S, Van Dycke A, Selzler KJ et al (2018) A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurol 18(1):188","journal-title":"BMC Neurol"},{"issue":"6","key":"1323_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dole\u017eil D, Silberstein S et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425\u2013434","journal-title":"Lancet Neurol"},{"issue":"22","key":"1323_CR5","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med 377(22):2113\u20132122","journal-title":"N Engl J Med"},{"issue":"24","key":"1323_CR6","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology. 91(24):e2211-21","journal-title":"Neurology."},{"issue":"1","key":"1323_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1526-4610.2010.01800.x","volume":"51","author":"JR Couch","year":"2011","unstructured":"Couch JR, for the Amitriptyline Versus Placebo Study Group (2011) Amitriptyline in the Prophylactic Treatment of Migraine and Chronic Daily Headache. Headache J Head Face Pain 51(1):33\u201351","journal-title":"Headache J Head Face Pain"},{"issue":"4","key":"1323_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1526-4610.2005.05068.x","volume":"45","author":"DW Dodick","year":"2005","unstructured":"Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD et al (2005) Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double-Blind, Placebo\u2010Controlled Study. Headache J Head Face Pain 45(4):315\u2013324","journal-title":"Headache J Head Face Pain"},{"issue":"4 Suppl 2","key":"1323_CR9","first-page":"23S","volume":"105","author":"SD Silberstein","year":"2005","unstructured":"Silberstein SD (2005) Chronic daily headache. J Am Osteopath Assoc 105(4 Suppl 2):23S\u201329S","journal-title":"J Am Osteopath Assoc"},{"issue":"3","key":"1323_CR10","first-page":"287","volume":"15","author":"MKA Welch","year":"2002","unstructured":"Welch MKA, Goadsby PJ (2002) Chronic daily headache: nosology and pathophysiology: Curr Opin Neurol. 15(3):287\u201395","journal-title":"Chronic daily headache: nosology and pathophysiology: Curr Opin Neurol."},{"issue":"8","key":"1323_CR11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1177\/0333102419847957","volume":"39","author":"DD Ruff","year":"2019","unstructured":"Ruff DD, Ford JH, Tockhorn-Heidenreich A, Sexson M, Govindan S, Pearlman EM et al (2019) Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure. Cephalalgia 39(8):931\u2013944","journal-title":"Cephalalgia"},{"issue":"18","key":"1323_CR12","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R et al (2020) Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study. Neurology 95(18):e2487\u2013e2499","journal-title":"Neurology"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-021-01323-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-021-01323-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-021-01323-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T13:07:51Z","timestamp":1632143271000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-021-01323-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,20]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1323"],"URL":"https:\/\/doi.org\/10.1186\/s10194-021-01323-6","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,20]]},"assertion":[{"value":"19 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The analysis was approved by the independent ethics committee of the University Hospital Essen (19-9004-BO) and all patients gave written consent to general analysis of their personal and clinical data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Martin Glas received honoraria from Novartis, UCB, Teva, Bayer, Novocure, Medac, Merck, Kyowa Kirin, has a consulting or advisory role to declare for Roche, Novartis, AbbVie, Novocure, and Daiichi Synkyo, and received travel fees from Novocure and Medac.Dagny Holle has received scientific support and\/or honoraria from Biogen, Novartis, Lilly, Sanofi-Aventis, Teva, Allergan, Hormosan.Christoph Kleinschnitz has received honoraria, a consulting or advisory role to declare for Alexion, Almirall, Amgen, Amicus, Bayer, Biogen, Biotronik, Boehringer Ingelheim, Bristol Myers-Squibb, Celgene, CSL Behring, Daiichi Sankyo, Desitin, Eisai, Ever Pharma, GE Healthcare, MedDay Pharmaceuticals, Merck Serono, Mylan, Novartis, Pfizer, Roche, Sanofi-Genzyme, Siemens, Stago, Teva.Michael Nsaka received travel fees from Licher MT.Armin Scheffler received travel fees from Teva, honoraria for participation on an advisory board of Novartis.Sebastian Wurthmann reports personal fees from Allergan, personal fees from Teva, personal fees from Novartis, outside the submitted work.Hannah Schenk declares that there is no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}